A 1-year, double-blind, randomized, placebo-controlled, study of rasagiline 1mg and 2mg added to Aricept [donepezil] 10mg daily in patients with mild to moderate dementia of the Alzheimer's type

Trial Profile

A 1-year, double-blind, randomized, placebo-controlled, study of rasagiline 1mg and 2mg added to Aricept [donepezil] 10mg daily in patients with mild to moderate dementia of the Alzheimer's type

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jan 2010

At a glance

  • Drugs Rasagiline (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 08 Apr 2008 Status changed from in progress to completed according to ClinicalTrials.gov.
    • 20 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top